Agenda
View Videos of the Conference:
Plenary Sessions Video
Concurrent Sessions Video
View Conference Photos
Photographs by Ed Cunicelli
Friday, June 23, 2023
PLENARY SESSION | EXHIBITS
In-Person: Check-In
Breakfast, Visit Exhibit Hall and View Posters
Virtual: Log-In and Visit Virtual Exhibit Hall
Welcome Remarks
Alison W. Loren, MD, MSCE | Penn Medicine
Alexis A. Thompson, MD, MPH | Children's Hospital of Philadelphia | Symposium Co-Chair
PLENARY SESSION 1: The Next Frontier is Here - Hemoglobinopathies
Moderator: Alexis A. Thompson, MD, MPH | Children's Hospital of Philadelphia | Symposium Co-Chair
Genome Edited Cell Based Medicines
Matthew Porteus, MD, PhD | Stanford University
Base Editing to Induce Fetal Hemoglobin Expression for Treating Sickle Cell Disease and Beta Thalassemia
Mitchell J. Weiss MD, PhD | St. Jude Children's Research Hospital
Risk of Malignancies and Curative Therapies for Hemoglobinopathies
John F. Tisdale, MD | National Heart, Lung and Blood Institute
Discussion
PLENARY SESSION 2: The Peril and the Promise of Cell Therapy in Solid Tumors
Moderator: Carl H. June, MD | Penn Medicine | Symposium Co-Chair
CAR T cells have shown robust efficacy in hematologic malignancies, however results in the more common solid tumors have been generally disappointing. In this session, Dr Maus will provide updates from research at Massachusetts General Hospital with a focus on brain cancer, and Dr. Narayan will provide updates on trials at PennMedicine in prostate cancer.
Two-in-One CAR-T Cells for Solid Tumors
Marcela V. Maus, MD, PhD | Massachusetts General Hospital
CAR-T Cell Therapy for Advanced Prostate Cancer: Clinical trials and tribulations
Vivek K. Narayan, MD, MS | Penn Medicine
Potency Enhancements to Improve CAR Efficacy against Solid Cancers
Crystal L. Mackall, MD | Stanford University
Discussion
BREAK
VISIT EXHIBITS
PLENARY SESSION 3: CAR T Cells Can Cure Patients: What are we waiting for?
Moderator: Stephan A. Grupp, MD, PhD | Children’s Hospital of Philadelphia | Symposium Co-Chair
Long Term Data in Lymphoma
Frederick Locke, MD | Moffitt Cancer Center
Curative Potential CART for ALL
Stephan A. Grupp, MD, PhD | Children’s Hospital of Philadelphia | Symposium Co-Chair
Expanding Access to CAR T Through Clinical Development
Harry Miao | Kite, A Gilead Company
Discussion
PLENARY SESSION 4: Cell and Gene Academia to Industry Translation
Moderator: Lindsey A. George, MD | Children’s Hospital of Philadelphia
This session will focus on academic and industry partnerships as well as academic-founded biotechnology start-ups for the development of gene-based therapies. Dr. George will present an overview of the current state of hemophilia gene therapy and how hemophilia has served as a model monogenic disorder for the development of gene-based therapies. Drs. Wilson and High will discuss commercial development of gene therapies and share their experiences bringing their work to clinical trial and being involved in academic start-up biotechnology companies as they enter public markets for the clinical development of gene therapy.
Hemophilia Gene Therapy
Lindsey A. George, MD | Children’s Hospital of Philadelphia
Gene Therapy: A case study for disruptive technology
James M. Wilson, MD, PhD | University of Pennsylvania
Perspectives on CHOP, Spark Therapeutics and AskBio
Katherine A. High, MD | Children’s Hospital of Philadelphia
Discussion
CLOSING REMARKS
Cellicon Valley Co-Chairs
ADJOURN
Lunch to Go